Clinical Trials Logo
  1. Home
  2. Neutropenia, Febrile
  3. NCT03217721

Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit — REANEUF  

Neutropenia, Febrile Clinical Trial

Official title:
Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit : New Recommendations do They Change Our Clinical Practice ?

Clinical Trial Summary

Neutropenia, defined by an absolute count of polymorphonuclear neutrophils less than <1500/mm3, exposes patients to infectious complications that can lead to sepsis or septic shock. The mortality risk is higher risk. The recommendations published in 2016 were formulated to homogenize the clinical practices to improve the survival.

Clinical Trial Description

We evaluate the adequacy antibiotics prescriptions in febrile neutropenia with suspected infection and evaluate factors influencing adequacy therapy and mortality consequence. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03217721
Study type Observational
Source University Hospital, Brest
Contact
Status Completed
Phase N/A
Start date June 19, 2017
Completion date September 19, 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04637464 - Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer N/A
Completed NCT03511820 - A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever
Not yet recruiting NCT04260230 - Remote Monitoring of Patients at Risk of Sepsis N/A
Completed NCT04187755 - Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever Phase 4
Completed NCT04669418 - Host RNA Signature in Children With Cancer and Infection
Recruiting NCT04938206 - DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule N/A
Terminated NCT03003273 - Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study Phase 3
Recruiting NCT05926063 - Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia Phase 4
Not yet recruiting NCT05852249 - Investigation of the Usability of Neutrocheck Amongst Healthy Volunteers and Healthcare Professionals.
Withdrawn NCT05061654 - CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients Phase 4
Recruiting NCT02474550 - Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma N/A